Mar. 23, 2026
9th Circuit revives FCA suit accusing drugmakers of overcharging government
Appellate court reinstates whistleblower case against major pharmaceutical companies, holding FCA claims can proceed independently of 340B enforcement limits.
The 9th U.S. Circuit Court of Appeals has breathed new life into a pharmaceutical whistleblower lawsuit, reversing a lower court's dismissal of a case alleging that several of the world's largest drug manufacturers overcharged the government by hundreds of millions of dollars.
The opinion written by Judge Roopali H. Desai rejected arguments by pharmaceutical heavyweights AbbVie, AstraZeneca, Novartis, and Sanofi that a qui tam action under the False Claims Act (FCA) broug...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In